Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Simon D. J. Gibbs"'
Autor:
Wilfrid J Jaksic, Cindy Lee, H. Miles Prince, Simon J. Harrison, Anna Kalff, Hang Quach, Peter Mollee, Dipti Talaulikar, Ken Romeril, Katherine Creeper, Douglas E. Joshua, Nicholas E. Murphy, Andrew C.W. Zannettino, Joy Ho, Ferenc Szabo, Henry Chan, Bradley Augustson, Simon D. J. Gibbs, Andrew Spencer, Jeff Szer, Anna Johnston, Nicholas Weber, Silvia Ling, John Gibson, Michael J. Fulham, Noemi Horvath, Kieran Kusel, Chris Ward
Publikováno v:
Internal Medicine Journal. 51:1707-1712
Imaging modalities for multiple myeloma (MM) have evolved to enable earlier detection of disease. Furthermore, the diagnosis of MM requiring therapy has recently changed to include disease prior to bone destruction, specifically the detection of foca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b592916f38d74c6198afae7290b52cc7
https://doi.org/10.1111/imj.15457
https://doi.org/10.1111/imj.15457
Autor:
Jin Lu, Kenshi Suzuki, Edward N. Libby, Dominique Chauveau, Xiang Qin, Giovanni Palladini, Hans C. Lee, Naresh Bumma, Katharine S. Gries, Moshe E. Gatt, Raymond L. Comenzo, Sandra Y. Vasey, Brendan M. Weiss, Jason Valent, Michael Rosenzweig, Arnaud Jaccard, Monique C. Minnema, Peter Mollee, Vaishali Sanchorawala, Meral Beksac, Jessica Vermeulen, Simon D. J. Gibbs, Kihyun Kim, Ashutosh Wechalekar, Christopher P. Venner, John Fastenau, Brenda Tromp, Stefan Schönland, Namphuong Tran, Vania Hungria, Sandy W. Wong, Giampaolo Merlini, M. Teresa Cibeira, Efstathios Kastritis
Publikováno v:
Blood. 136:37-40
Background: Systemic AL amyloidosis is a rare disease characterized by amyloid fibril deposits, most commonly in the heart and kidneys; there are currently no health authority-approved treatments. Therapies for the treatment of multiple myeloma (MM),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58aeaf75e83a764541519175f2965f85
https://doi.org/10.1182/blood-2020-139438
https://doi.org/10.1182/blood-2020-139438
Autor:
Jonathan L. Kaufman, Nizar J. Bahlis, Vasudha Sehgal, Simon J. Harrison, Philippe Moreau, Simon D. J. Gibbs, Jeremy A. Ross, Shir-Jing Ho, Hang Quach, Rachid Baz, Eva Medvedova, Torben Plesner, L. Leanne Lash-Fleming, Yan Luo, Kingston Kang, Annette Juul Vangsted
Publikováno v:
Kaufman, J L, Quach, H, Baz, R, Vangsted, A J, Ho, S-J, Harrison, S J, Plesner, T, Moreau, P, Gibbs, S D, Medvedova, E, Sehgal, V, Kang, K, Ross, J A, Lash-Fleming, L L, Luo, Y & Bahlis, N J 2021, ' Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma ', Blood, vol. 138, no. Suppl .1, 817 . https://doi.org/10.1182/blood-2021-146043
Background: Current therapies for multiple myeloma (MM) delay disease progression and prolong survival but most patients (pts) eventually relapse or become refractory (RR). Daratumumab (D), an anti-CD38 antibody (Ab), plus bortezomib (V), a proteasom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491c9a8772a2a3d0e79319a202a906f6
https://portal.findresearcher.sdu.dk/da/publications/9fca9ece-958d-4a29-8d86-001677e8a398
https://portal.findresearcher.sdu.dk/da/publications/9fca9ece-958d-4a29-8d86-001677e8a398
Autor:
Jonathan L. Kaufman, Nizar J. Bahlis, Jeremy A. Ross, Simon D. J. Gibbs, Yan Luo, Torben Plesner, Christine Mantis, Eva Medvedova, Philippe Moreau, Deeksha Vishwamitra, Shir-Jing Ho, Orlando F. Bueno, Annette Juul Vangsted, Hang Quach, Rachid Baz, Simon J. Harrison
Publikováno v:
Bahlis, N J, Kaufman, J L, Baz, R, Quach, H, Ho, S-J, Vangsted, A J, Plesner, T, Moreau, P, Gibbs, S D, Medvedova, E, Bueno, O F, Luo, Y, Mantis, C, Vishwamitra, D, Ross, J A & Harrison, S J 2021, ' Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone ', Blood, vol. 138, no. Suppl. 1, 1633 . https://doi.org/10.1182/blood-2021-146012
Background: Venetoclax (Ven) is a highly selective, potent, oral BCL-2 inhibitor that is currently being evaluated as a targeted therapy for the treatment of t(11;14) relapsed/refractory multiple myeloma (RRMM). The combination of Ven with daratumuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7b3429a1aff23dbdd303436f7b5654
https://portal.findresearcher.sdu.dk/da/publications/2aab7aad-040e-4740-a8b6-1754586ba081
https://portal.findresearcher.sdu.dk/da/publications/2aab7aad-040e-4740-a8b6-1754586ba081
Autor:
Annette Juul Vangsted, Abdullah A. Masud, Jeremy A. Ross, Simon J. Harrison, Shir-Jing Ho, Torben Plesner, Hang Quach, Nizar J. Bahlis, Rachid Baz, Orlando F. Bueno, Sheryl Coppola, Xiaoqing Yang, Simon D. J. Gibbs, Jonathan L. Kaufman, Philippe Moreau
Publikováno v:
Bahlis, N J, Baz, R, Harrison, S J, Quach, H, Ho, S J, Vangsted, A J, Plesner, T, Moreau, P, Gibbs, S D, Coppola, S, Yang, X, Al Masud, A, Ross, J A, Bueno, O & Kaufman, J L 2021, ' Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3602-3612 . https://doi.org/10.1200/JCO.21.00443
PURPOSE Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60661302a7ea9152573f073b9a8edd6
https://pubmed.ncbi.nlm.nih.gov/34388020
https://pubmed.ncbi.nlm.nih.gov/34388020
Autor:
Mark S. Taylor, Hasib Sidiqi, James Hare, Fiona Kwok, Bo Choi, Darren Lee, Jay Baumwol, Antonia S. Carroll, Steve Vucic, Pat Neely, Dariusz Korczyk, Liza Thomas, Peter Mollee, Graeme J. Stewart, Simon D. J. Gibbs
Publikováno v:
Internal medicine journalReferences.
Amyloidosis is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. While these fibrils may aggregate to form insignificant localised deposits, they can also accumulate in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a60fadcc7cea30241e41cad5271dbd69
https://pubmed.ncbi.nlm.nih.gov/36478370
https://pubmed.ncbi.nlm.nih.gov/36478370
Autor:
Sandy W. Wong, Edward N. Libby, Giampaolo Merlini, Giovanni Palladini, Brendan M. Weiss, Naresh Bumma, Kihyun Kim, Meletios A. Dimopoulos, Hans C. Lee, Vania Hungria, M. Teresa Cibeira, Raymond L. Comenzo, Efstathios Kastritis, Monique C. Minnema, Jessica Vermeulen, Namphuong Tran, Brenda Tromp, Jason Valent, Meral Beksac, Simon D. J. Gibbs, Xiang Qin, Arnaud Jaccard, Vaishali Sanchorawala, Peter Mollee, Jin Lu, Kenshi Suzuki, Dominique Chauveau, Christopher P. Venner, Ashutosh D. Wechalekar, Stefan Schönland, Michael Rosenzweig, Sandra Y. Vasey, Moshe E. Gatt
Publikováno v:
Blood. 136:48-50
Background: Systemic AL amyloidosis is characterized by the deposition of insoluble amyloid fibrils produced by light chains synthesized by clonal CD38+ plasma cells. Combining daratumumab (DARA) with bortezomib, cyclophosphamide, and dexamethasone (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4843eaf5a5805f2bed39b15f40498b44
https://doi.org/10.1182/blood-2020-137582
https://doi.org/10.1182/blood-2020-137582
Autor:
Peter M. Voorhees, Maria M. Picken, Virginie Royal, Samih H. Nasr, Christopher P. Venner, Glen S. Markowitz, Guillermo A. Herrera, Aristeidis Chaidos, Efstathios Kastritis, Vishal Kukreti, Julian D. Gillmore, Angela Dispenzieri, Sanjeev Sethi, Brendan M. Weiss, Peter Mollee, Helen J. Lachmann, Simon D. J. Gibbs, Arnaud Jaccard, Heinz Ludwig, Giampaolo Merlini, Jean Paul Fermand, Robert A. Kyle, Frank Bridoux, Paul W. Sanders, Vivette D. D'Agati, Dragan Jevremovic, Ashutosh D. Wechalekar, Vecihi Batuman, Vincent Rajkumar, Fernando C. Fervenza, Nelson Leung, Paul Cockwell, Christopher P. Larsen
Publikováno v:
Nature Reviews. Nephrology
The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnostic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4f97bc4fc30a973943de27052652bf
http://europepmc.org/articles/PMC7136169
http://europepmc.org/articles/PMC7136169
Autor:
Georgia McCaughan, Tara Cochrane, Anna Johnston, Mark N. Polizzotto, Anoop K Enjeti, Matthew Greenwood, Pietro R Di Ciaccio, Jennifer Curnow, Leanne Berkahn, Joel Wight, Michael Dickinson, Benjamin W Teh, Maya Latimer, Simon D. J. Gibbs, H. Miles Prince, Jeff Szer, P. Joy Ho, Michelle Ananda-Rajah, Robert Weinkove, Matthew Ku, Judith Trotman, David M. Ross, Hang Quach, Gareth P. Gregory, Tasman Armytage, Greg Hapgood, Raina MacIntyre, Constantine S. Tam, Nada Hamad, Andrew H. Wei, Chan Cheah, Shane A Gangatharan, Stephen P. Mulligan, Nicole Gilroy, Phillip Choi
Publikováno v:
Internal Medicine Journal
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af19b6bc79b5f0600ff1c08f6fa70d3e
https://pubmed.ncbi.nlm.nih.gov/34047035
https://pubmed.ncbi.nlm.nih.gov/34047035
Autor:
Michael Dickinson, Richard Doocey, Maya Latimer, Cindy Lee, Simon D. J. Gibbs, Joel Wight, Pietro R Di Ciaccio, Matthew Ku, Robin Gasiorowski, Shane A Gangatharan, Hang Quach, Hui Peng Lee, Stephen P. Mulligan, Robert Weinkove, Leanne Berkhahn, Chan Yoon Cheah, Mark N. Polizzotto, Simon J. Harrison, Andrew Spencer, Constantine S. Tam, Phoebe Joy Ho, Tasman Armytage, Anna Johnston, Scott Chapman, Nicholas Webber, Belinda A. Campbell, Henry Miles Prince, Tara Cochrane, Georgia McCaughan, Nada Hamad, Judith Trotman, Greg Hapgood, Gareth P. Gregory
Publikováno v:
Internal Medicine Journal
The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d358c2c4635fec8685a781b129057ce
https://hdl.handle.net/2123/22538
https://hdl.handle.net/2123/22538